Efficacy and safety of daclatasvir-based antiviral therapy in HCV recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multi-centre cohort study.

June 21, 2017

Publications

>

Article

Sí

Efficacy and safety of daclatasvir-based antiviral therapy in HCV recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multi-centre cohort study.

Publicated to:Transplant International. 30 (10): 1041-1050 - 2017-10-01 30(10), DOI: 10.1111/tri.12999

Authors: Salcedo, Magdalena; Prieto, Martin; Castells, Lluis; Manuel Pascasio, Juan; Montero Alvarez, Jose Luis; Fernandez, Inmaculada; Sanchez-Antolin, Gloria; Gonzalez-Dieguez, Luisa; Garcia-Gonzalez, Miguel; Otero, Alejandra; Lorente, Sara; Dolores Espinosa, Maria; Testillano, Milagros; Gonzalez, Antonio; Castellote, Jose; Casafont, Fernando; Londono, Maria-Carlota; Antonio Pons, Jose; Cuervas-Mons, Valentin; Pascual, Sonia; Ignacio Herrero, Jose; Narvaez, Isidoro; Vinaixa, Carmen; Llaneras, Jordi; Manuel Sousa, Jose; Banares, Rafael

Affiliations

Clin Univ Navarra, Inst Invest Sanitaria Navarra IdiSNA, CIBERehd, Liver Unit, Navarra, Spain CIBER - Centro de Investigacion Biomedica en Red CIBEREHD University of Navarra - Author

Complejo Hosp Univ Badajoz Infanta Cristina, Liver Transplantat Unit, Gastroenterol Dept, Badajoz, Spain - Author

Complejo Hosp Univ Granada, Liver Unit, UGC Digest Dis, Granada, Spain University of Granada - Author

Hosp Clin Barcelona, Liver Unit, CIBERehd, Barcelona, Spain CIBEREHD University of Barcelona Hospital Clinic de Barcelona CIBER - Centro de Investigacion Biomedica en Red - Author

Hosp Clin Lozano Blesa Zaragoza, IIS Aragon, Digest Dis Dept, Zaragoza, Spain Lozano Blesa University Clinical Hospital - Author

Hosp Clin Univ Santiago de Compostela, Abdominal Transplants Unit, Santiago De Compostela, Spain Complexo Hospitalario Universitario de Santiago de Compostela - Author

Hosp Clin Univ Virgen Arrixaca, Liver Unit, Murcia, Spain Hospital Clinico Universitario Virgen de la Arrixaca - Author

Hosp Gen Univ Alicante, Liver Unit, Gastroenterol Dept, CIBERehd, Alicante, Spain CIBEREHD General University Hospital of Alicante CIBER - Centro de Investigacion Biomedica en Red - Author

Hosp Gen Univ Gregorio Maranon, Liver Unit, Dr Esquerdo 46, Madrid 28007, Spain. General University Gregorio Maranon Hospital - Author

Hosp Gen Valle Hebron, Liver Unit, Internal Med Dept, Barcelona, Spain Hospital Universitari Vall d'Hebron - Author

Hosp Ramon &Cajal, Digest Dis Dept, Madrid, Spain Hospital Universitario Ramon y Cajal - Author

Hosp Univ & Politecn La Fe, Gastroenterol Dept, CIBERehd, Valencia, Spain CIBER - Centro de Investigacion Biomedica en Red CIBEREHD Hospital Universitari i Politecnic La Fe - Author

Hosp Univ & Politecn La Fe, Liver Unit, Gastroenterol Dept, CIBERehd, Valencia, Spain CIBEREHD Hospital Universitari i Politecnic La Fe CIBER - Centro de Investigacion Biomedica en Red - Author

Hosp Univ 12 Octubre, Digest Dis Serv, Madrid, Spain Hospital Universitario 12 de Octubre - Author

Hosp Univ A Coruna, Liver Unit, La Coruna, Spain Complejo Hospitalario Universitario A Coruna - Author

Hosp Univ Cent Asturias, Liver Unit, Oviedo, Spain Central University Hospital Asturias - Author

Hosp Univ Cruces, Liver Unit & Liver Transplantat, Bilbao, Spain Hospital Universitario Cruces - Author

Hosp Univ Marques Valdecilla, Dept Gastroenterol, Santander, Spain Hospital Universitario Marques de Valdecilla (HUMV) - Author

Hosp Univ Reina Sofia, Hepatol Unit, Cordoba, Spain Hospital Universitario Reina Sofia - Author

Hosp Univ Rio Hortega, Liver Unit, Liver Transplantat Unit, Valladolid, Spain Hospital del Rio Hortega - Author

Hosp Univ Virgen Rocio, UGC Digest Dis, CIBERehd, Seville, Spain CIBEREHD Virgen del Rocio University Hospital CIBER - Centro de Investigacion Biomedica en Red - Author

Hosp Univ Virgen Rocio, UGC Unit, Digest Dis, Seville, Spain Virgen del Rocio University Hospital - Author

Univ Autonoma Barcelona, Liver Unit, Internal Med Dept, Hosp Gen Vall dHebron,CIBERehd, Barcelona, Spain CIBEREHD CIBER - Centro de Investigacion Biomedica en Red Autonomous University of Barcelona - Author

Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Liver Transplant Unit, Dept Med, Madrid, Spain Autonomous University of Madrid Hospital Puerta de Hierro-Majadahonda - Author

Univ Barcelona, Hosp Univ Bellvitge, Digest Dis Dept, IDIBELL, Barcelona, Spain Bellvitge University Hospital Catalan Health Institute University of Barcelona - Author

Univ Complutense, Digest Dis Dept, IISGM, CIBERehd, Madrid, Spain CIBER - Centro de Investigacion Biomedica en Red Complutense University of Madrid CIBEREHD - Author

Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERehd, Digest Dis Dept,Fac Med,IISGM, Madrid, Spain CIBER - Centro de Investigacion Biomedica en Red CIBEREHD General University Gregorio Maranon Hospital Complutense University of Madrid - Author

Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERehd, Liver Transplant Unit,Fac Med,IISGM, Madrid, Spain General University Gregorio Maranon Hospital CIBEREHD Complutense University of Madrid CIBER - Centro de Investigacion Biomedica en Red - Author

Univ Complutense, Hosp Gen Univ Gregorio Maranon, Liver Transplant Unit, Madrid, Spain Complutense University of Madrid General University Gregorio Maranon Hospital - Author

Univ Ntra Sra Candelaria, Liver Unit, Tenerife, Spain - Author

Abstract

Direct-acting antiviral agents (DAA) combining daclatasvir (DCV) have reported good outcomes in the recurrence of hepatitis C virus (HCV) infection after liver transplant (LT). However, its effect on the severe recurrence and the risk of death remains controversial. We evaluated the efficacy, predictors of survival, and safety of DAC-based regimens in a large real-world cohort. A total of 331 patients received DCV-based therapy. Duration of therapy and ribavirin use were at the investigator's discretion. The primary end point was sustained virological response (SVR) at week 12. A multivariate analysis of predictive factors of mortality was performed. Intention-to-treat (ITT) and per-protocol SVR were 93.05% and 96.9%. ITT-SVR was lower in cirrhosis (n = 163) (96.4% vs. 89.6% P = 0.017); the SVR in genotype 3 (n = 91) was similar, even in advanced fibrosis (96.7% vs. 88%, P = 0.2). Ten patients (3%) experienced virological failure. Therapy was stopped in 18 patients (5.44%), and ten died during treatment. A total of 22 patients (6.6%) died. Albumin (HR = 0.376; 95% CI 0.155-0.910) and baseline MELD (HR = 1.137; 95% CI: 1.061-1.218) were predictors of death. DCV-based DAA treatment is efficacious and safe in patients with HCV infection after LT. Baseline MELD score and serum albumin are predictors of survival irrespective of viral response.© 2017 Steunstichting ESOT.

Keywords

DaclatasvirEfficacy and safetyModel for end-stage liver diseaseRecurrence of hcvSurvival prognostic model

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Transplant International due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2017, it was in position 38/200, thus managing to position itself as a Q1 (Primer Cuartil), in the category Surgery.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.43, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-22, the following number of citations:

WoS: 7
Scopus: 8
Europe PMC: 1

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Granada.

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share

Efficacy and safety of daclatasvir-based antiviral therapy in HCV recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multi-centre cohort study.

Affiliations

Abstract

Keywords

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

Impact and social visibility

Leadership analysis of institutional authors